Akamis Bio Reports Promising Early Phase 1b FORTRESS Results for NG-350A in MMR-Proficient Locally Advanced Rectal Cancer

Akamis Bio Reports Promising Early Findings from Phase 1b FORTRESS Trial of NG-350A in MMR-Proficient Locally Advanced Rectal Cancer Akamis Bio, a biotechnology company focused on transforming the treatment landscape…

Read MoreAkamis Bio Reports Promising Early Phase 1b FORTRESS Results for NG-350A in MMR-Proficient Locally Advanced Rectal Cancer

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) to Prevent RSV Lower Respiratory Disease in Infants

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season Merck & Co.—known as MSD…

Read MoreEuropean Commission Approves Merck’s ENFLONSIA™ (clesrovimab) to Prevent RSV Lower Respiratory Disease in Infants

Drug Farm to Present Encouraging Phase 1b Results for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™ Drug Farm has announced promising early clinical and immunologic data from its…

Read MoreDrug Farm to Present Encouraging Phase 1b Results for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

Bruker Enhances MALDI Biotyper® and IR Biotyper® Workflows for Advanced Microbial Identification and Outbreak Control

Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management At the ESCMID Global 2026, Bruker Corporation unveiled a wide-ranging set of portfolio enhancements spanning microbial identification,…

Read MoreBruker Enhances MALDI Biotyper® and IR Biotyper® Workflows for Advanced Microbial Identification and Outbreak Control

Bruker Unveils MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026

Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 At the ESCMID Global 2026, the Microbiology & Infection Diagnostics division of Bruker Corporation unveiled a major advancement in…

Read MoreBruker Unveils MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
WuXi Biologics

WuXi Biologics Secures ISO 13485 Certification for Drug–Device Development and Manufacturing

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug–Device Combination Product Development and Manufacturing WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced…

Read MoreWuXi Biologics Secures ISO 13485 Certification for Drug–Device Development and Manufacturing